Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Coherus Biosciences ( (CHRS) ) has shared an announcement.
Coherus BioSciences has entered an agreement to sell its UDENYCA® franchise to Intas Pharmaceuticals for up to $558.4 million. This deal includes an upfront cash payment of $483.4 million, with potential milestone payments of $75 million based on net sales achievements. The divestiture aims to strengthen Coherus’ focus on its innovative immuno-oncology programs, such as LOQTORZI®, and improve financial health by repaying convertible notes and reducing liabilities. The transaction is expected to close by Q1 2025, subject to customary closing conditions.
For an in-depth examination of CHRS stock, go to TipRanks’ Stock Analysis page.
